Eli Lilly And Company (LLY)

$746.2

-40.03

(-5.09%)▲

Market is closed - opens 8 PM, 18 Nov 2024
star icon

Eli Lilly And Co is a pharmaceutical company that develops and sells prescription drugs in various therapeutic areas, including neuroscience, oncology, and endocrinology.

Performance

  • $744.72
    $775.91
    $746.20
    downward going graph

    0.2%

    Downside

    Day's Volatility :4.02%

    Upside

    3.83%

    downward going graph
  • $561.65
    $972.53
    $746.20
    downward going graph

    24.73%

    Downside

    52 Weeks Volatility :42.25%

    Upside

    23.27%

    downward going graph

Returns

PeriodEli Lilly And CompanySector (Health Care)S&P500
3 Months
-19.05%
-7.2%
5.7%
6 Months
-3.09%
-3.1%
10.7%
1 Year
26.11%
10.6%
30.1%
3 Years
185.7%
6.1%
25.2%

Highlights

Market Capitalization
746.4B
Book Value
$15.83
Dividend Share
5.03
Dividend Yield
0.66%
Earnings Per Share (EPS)
8.81
PE Ratio
84.7
PEG Ratio
0.74
Wall Street Target Price
992.182
Profit Margin
20.48%
Operating Margin TTM
39.77%
Return On Assets TTM
13.95%
Return On Equity TTM
65.32%
Revenue TTM
40.9B
Revenue Per Share TTM
45.37
Quarterly Revenue Growth YOY
20.4%
Gross Profit TTM
21.9B
EBITDA
16.6B
Diluted Eps TTM
8.81
Quarterly Earnings Growth YOY
0.68
EPS Estimate Current Year
13.16
EPS Estimate Next Year
22.6
EPS Estimate Current Quarter
1.47
EPS Estimate Next Quarter
5.47

Analyst Recommendation

Buy
    75%Buy
    25%Hold
    0
    0%Sell
Based on 32 Wall street analysts offering stock ratings for Eli Lilly And Company(by analysts ranked 0 to 5 stars)
Based on 32 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
24
24
25
Hold
8
8
6
Sell
00
00
1

Analyst Forecast

What analysts predicted

Upside of 32.96%

Current $746.20
Target $992.18

Company Financials

FY18Y/Y Change
Revenue
21.5B
↓ 6.03%
Net Income
3.2B
↓ 1683.54%
Net Profit Margin
15.04%
↑ 15.93%
FY19Y/Y Change
Revenue
22.3B
↑ 3.84%
Net Income
4.6B
↑ 43.5%
Net Profit Margin
20.78%
↑ 5.74%
FY20Y/Y Change
Revenue
24.5B
↑ 9.95%
Net Income
6.2B
↑ 33.55%
Net Profit Margin
25.24%
↑ 4.46%
FY21Y/Y Change
Revenue
28.3B
↑ 15.4%
Net Income
5.6B
↓ 9.88%
Net Profit Margin
19.71%
↓ 5.53%
FY22Y/Y Change
Revenue
28.5B
↑ 0.79%
Net Income
6.2B
↑ 11.88%
Net Profit Margin
21.88%
↑ 2.17%
FY23Y/Y Change
Revenue
34.1B
↑ 19.56%
Net Income
5.2B
↓ 16.08%
Net Profit Margin
15.36%
↓ 6.52%
Q2 FY23Q/Q Change
Revenue
8.3B
↑ 19.43%
Net Income
1.8B
↑ 31.1%
Net Profit Margin
21.21%
↑ 1.89%
Q3 FY23Q/Q Change
Revenue
9.5B
↑ 14.27%
Net Income
-57.4M
↓ 103.26%
Net Profit Margin
-0.6%
↓ 21.81%
Q4 FY23Q/Q Change
Revenue
9.4B
↓ 1.53%
Net Income
2.2B
↓ 3914.81%
Net Profit Margin
23.41%
↑ 24.01%
Q1 FY24Q/Q Change
Revenue
8.8B
↓ 6.26%
Net Income
2.2B
↑ 2.43%
Net Profit Margin
25.58%
↑ 2.17%
Q2 FY24Q/Q Change
Revenue
11.3B
↑ 28.91%
Net Income
3.0B
↑ 32.28%
Net Profit Margin
26.25%
↑ 0.67%
Q3 FY24Q/Q Change
Revenue
11.4B
↑ 1.21%
Net Income
970.3M
↓ 67.3%
Net Profit Margin
8.48%
↓ 17.77%
FY18Y/Y Change
Total Assets
43.9B
↓ 2.38%
Total Liabilities
33.0B
↓ 0.94%
FY19Y/Y Change
Total Assets
39.3B
↓ 10.53%
Total Liabilities
36.6B
↑ 10.87%
FY20Y/Y Change
Total Assets
46.6B
↑ 18.7%
Total Liabilities
40.8B
↑ 11.54%
FY21Y/Y Change
Total Assets
48.8B
↑ 4.66%
Total Liabilities
39.7B
↓ 2.83%
FY22Y/Y Change
Total Assets
49.5B
↑ 1.4%
Total Liabilities
38.7B
↓ 2.36%
FY23Y/Y Change
Total Assets
64.0B
↑ 29.33%
Total Liabilities
53.1B
↑ 37.27%
Q2 FY23Q/Q Change
Total Assets
54.8B
↑ 3.11%
Total Liabilities
43.7B
↑ 4.29%
Q3 FY23Q/Q Change
Total Assets
57.9B
↑ 5.66%
Total Liabilities
46.6B
↑ 6.74%
Q4 FY23Q/Q Change
Total Assets
64.0B
↑ 10.52%
Total Liabilities
53.1B
↑ 14.02%
Q1 FY24Q/Q Change
Total Assets
63.9B
↓ 0.1%
Total Liabilities
51.0B
↓ 3.95%
Q2 FY24Q/Q Change
Total Assets
71.9B
↑ 12.4%
Total Liabilities
58.2B
↑ 14.09%
Q3 FY24Q/Q Change
Total Assets
75.6B
↑ 5.19%
Total Liabilities
61.3B
↑ 5.23%
FY18Y/Y Change
Operating Cash Flow
5.5B
↓ 1.62%
Investing Cash Flow
1.9B
↓ 150.38%
Financing Cash Flow
-5.9B
↓ 4240.88%
FY19Y/Y Change
Operating Cash Flow
4.8B
↓ 12.45%
Investing Cash Flow
-8.1B
↓ 524.08%
Financing Cash Flow
-2.3B
↓ 60.63%
FY20Y/Y Change
Operating Cash Flow
6.5B
↑ 34.38%
Investing Cash Flow
-2.3B
↓ 72.05%
Financing Cash Flow
-3.1B
↑ 34.96%
FY21Y/Y Change
Operating Cash Flow
7.3B
↑ 11.71%
Investing Cash Flow
-2.9B
↑ 26.94%
Financing Cash Flow
-4.1B
↑ 31.69%
FY22Y/Y Change
Operating Cash Flow
7.1B
↓ 2.43%
Investing Cash Flow
-3.8B
↑ 31.23%
Financing Cash Flow
-5.4B
↑ 30.87%
FY23Y/Y Change
Operating Cash Flow
4.2B
↓ 40.15%
Investing Cash Flow
-7.2B
↑ 90.08%
Financing Cash Flow
3.5B
↓ 164.65%
Q2 FY23Q/Q Change
Operating Cash Flow
631.9M
↓ 63.49%
Investing Cash Flow
-459.1M
↓ 33.35%
Financing Cash Flow
-1.0B
↓ 350.64%
Q3 FY23Q/Q Change
Operating Cash Flow
2.2B
↑ 246.49%
Investing Cash Flow
-3.1B
↑ 570.99%
Financing Cash Flow
572.0M
↓ 155.35%
Q4 FY23Q/Q Change
Operating Cash Flow
-311.9M
↓ 114.25%
Investing Cash Flow
-2.9B
↓ 5.07%
Financing Cash Flow
3.5B
↑ 519.7%
Q1 FY24Q/Q Change
Operating Cash Flow
1.2B
↓ 473.84%
Investing Cash Flow
-1.2B
↓ 59.73%
Financing Cash Flow
-311.3M
↓ 108.78%

Technicals Summary

Sell

Neutral

Buy

Eli Lilly And Company is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Eli Lilly And Company
Eli Lilly And Company
-18.64%
-3.09%
26.11%
185.7%
554.16%
Johnson & Johnson
Johnson & Johnson
-6.37%
-0.41%
2.81%
-5.68%
14.22%
Pfizer Inc.
Pfizer Inc.
-15.27%
-13.41%
-17.11%
-51.25%
-33.37%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Eli Lilly And Company
Eli Lilly And Company
84.7
84.7
0.74
13.16
0.65
0.14
0.01
15.83
Johnson & Johnson
Johnson & Johnson
25.14
25.14
0.91
9.95
0.21
0.08
0.03
29.14
Pfizer Inc.
Pfizer Inc.
34.69
34.69
0.19
2.93
0.05
0.03
0.06
16.29
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Eli Lilly And Company
Eli Lilly And Company
Buy
$746.4B
554.16%
84.7
20.48%
Johnson & Johnson
Johnson & Johnson
Buy
$365.6B
14.22%
25.14
16.74%
Pfizer Inc.
Pfizer Inc.
Hold
$147.5B
-33.37%
34.69
7.16%

Insights on Eli Lilly And Company

  • Increasing Revenue

    Revenue is up for the last 3 quarters, 8.76B → 11.43B (in $), with an average increase of 11.8% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, 2.96B → 970.3M (in $), with an average decrease of 67.3% per quarter

Institutional Holdings

  • Lilly Endowment Inc

    10.21%

  • Vanguard Group Inc

    7.78%

  • BlackRock Inc

    6.94%

  • PNC Financial Services Group Inc

    5.41%

  • State Street Corp

    3.57%

  • FMR Inc

    3.53%

Corporate Announcements

  • Eli Lilly And Company Dividends March,2024

    In the quarter ending March,2024. Eli Lilly And Company has declared dividend of $1.30

    Read More

Company Information

Lilly (Eli) & Co. is an American-based multinational pharma company with offices in 18 countries. Its headquarters are situated in Indianapolis, Indiana, and it sells drugs in over 125 countries. Colonel Eli Lilly was a pharmaceutical chemist and American Civil War veteran who founded this company in 1876. It is traded as LLY in the New York Stock Exchange (NYSE). Lilly employs over 33,000 people and generated a revenue of over 22 billion USD as of 2019. The company is committed to researching and developing high-quality drugs for humankind's welfare by remaining true to its work. In 1876, this company produced the medicinal drug called quinine used in the treatment of Malaria. Among its many commendable innovations were gelatin-coating for the capsules & pills and sugar-coated pills that make them easier to swallow. It also developed various drugs for treating syphilis, rheumatism, eczema, and psoriasis in the early 1880s. A scientific journal asserted that the Lilly operation was the largest capsule factory in the world in 1917. In 1923, Lilly mass-produced the Insulin under the name “Iletin” used to treat diabetes in the US. Moreover, it also became the company to mass-produce Penicillin in the 1940s and started producing the Polio vaccine in the early 1950s. It acquired CoLucid in 20017 for 960mn USD and Armo Biosciences for 1.6bn USD in 2018. Also, it purchased the Aurora Kinase A, an inhibitor developer, for 575mn USD. It acquired multiple companies for developing and researching breakthroughs. The company aims to bring life-changing research to the community while performing voluntary & philanthropist operations worldwide. Currently Eli Lilly And Company has a market cap of $893.59 Billion. It has a P.E ratio of 121.71. The shares of Eli Lilly And Company are trading at $746.2. .

Organization
Eli Lilly And Company
Employees
43000
CEO
Mr. David A. Ricks
Industry
Health Technology

FAQs